Merck's Keytruda approved as the first-line dual immune therapy for non-small cell lung cancer in China

According to Bristol-Myers Squibb, its Opdivo in combination with Yervoy regimen has been approved by the National Medical Products Administration for the first-line treatment of metastatic non-small cell lung cancer with a PD-L1 tumor proportion score 1%, negative for epidermal growth factor receptor gene mutation and anaplastic lymphoma kinase negative. This combination therapy is the first approved lung cancer dual immunotherapy in China, providing a new option for long-term survival without chemotherapy for the indicated patients.